Jazz Pharmaceuticals Stock Forecast & Price Prediction 2026-2027

Algorithmic price targets and analysis for JAZZ based on fundamentals, valuation multiples, and historical data.

$178.55-1.66%
Bearish

Price Target Summary

Bear Case
$142.84
-20.0% from current
Base Case
$168.85
-5.4% from current
Bull Case
$303.93
+70.2% from current

Technical Outlook

52-Week Range Analysis

$95.49$198.00
Current: $178.55
Support Level
$105.74
Resistance Level
$187.75
From 52W High
-9.8%
From 52W Low
+87.0%

Fundamental Analysis

Revenue Growth Projection

Year 1 Projected
$4.16B
Year 2 Projected
$4.16B
Year 3 Projected
$4.16B

Based on +0.0% YoY growth, tapered 20% per year in outer projections.

Valuation vs Peers

Current P/S
2.64x
Sector Median P/S
2.5x
Assessment
In-line with sector

Cash Position

Cash on Hand
N/A
Total Debt
$5.36B

Key Metrics

Current Price$178.55
Market Cap$10.99B
P/S Ratio2.64x
Revenue (TTM)$4.16B
Revenue Growth (YoY)+0.0%
Gross MarginN/A
Cash on HandN/A
Total Debt$5.36B
52W High$198.00
52W Low$95.49

Signal Breakdown

Overall Signal: Bearish
  • Negative or flat revenue growth
  • Total debt exceeds cash position
  • Trading near 52-week highs

Risk Factors

  • High debt-to-cash ratio: total debt of $5.36B significantly exceeds cash of $0.

Analyst Summary

Jazz Pharmaceuticals (JAZZ) is a Biotech cannabis company with contracting revenue and a market capitalization of $10.99B. Based on trailing revenue of $4.16B and a P/S ratio of 2.64x, the stock is fairly valued relative to the sector median of 2.5x. Our algorithmic base-case price target of $168.85 implies downside of 5.4% from current levels. The overall signal is bearish, as several fundamental metrics are under pressure. Investors should weigh the 1 identified risk factor before making any investment decision.

Frequently Asked Questions

What is the price target for JAZZ?+
Our algorithmic base-case price target for Jazz Pharmaceuticals (JAZZ) is $168.85, with a bear case of $142.84 and a bull case of $303.93. These targets are derived from sector-average and premium P/S multiples applied to projected revenue.
Is JAZZ a buy right now?+
Based on our algorithmic analysis, JAZZ currently carries a bearish signal. Negative or flat revenue growth. Total debt exceeds cash position. This is not a buy or sell recommendation — always do your own due diligence.
What is the revenue forecast for Jazz Pharmaceuticals?+
Based on the current year-over-year growth rate of +0.0%, we project JAZZ revenue at $4.16B in Year 1, $4.16B in Year 2, and $4.16B in Year 3. Growth rates are tapered in outer years.
What are the risks of investing in JAZZ?+
High debt-to-cash ratio: total debt of $5.36B significantly exceeds cash of $0.
How does JAZZ valuation compare to the cannabis sector?+
JAZZ has a trailing P/S ratio of 2.64x compared to the cannabis sector median of 2.5x. The stock in-line with sector.

Important Disclaimer

This is not financial advice. Forecasts are algorithmic projections based on historical data and should not be used as the sole basis for investment decisions. Past performance does not guarantee future results. Cannabis stocks carry significant risk including regulatory, market, and operational risks. Always consult with a qualified financial advisor before making investment decisions. Cannabismarketcap does not recommend buying, selling, or holding any security.

← Back to JAZZ OverviewAll Cannabis Stocks